Photodynamic Therapy for Field Cancerization in the Skin: Where Do We Stand?

被引:2
|
作者
Bakirtzi, Katerina [1 ,2 ]
Papadimitriou, Ilias [1 ]
Vakirlis, Efstratios [1 ]
Lallas, Aimilios [1 ]
Sotiriou, Eleni [1 ]
机构
[1] Aristotle Univ Thessaloniki, Dept Dermatol & Venereol 1, Thessaloniki, Greece
[2] Aristotle Univ Thessaloniki, Delfon 124,POB 54643, Thessaloniki, Greece
来源
DERMATOLOGY PRACTICAL & CONCEPTUAL | 2023年 / 13卷 / 04期
关键词
actinic keratosis; photodynamic therapy; skin field cancerization; METHYL-AMINOLEVULINATE; ACTINIC KERATOSES; 5-AMINOLEVULINIC ACID; BF-200; ALA; TRANSPLANT RECIPIENTS; RANDOMIZED-TRIAL; DOUBLE-BLIND; PHASE-III; EFFICACY; FACE;
D O I
10.5826/dpc.1304a291
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Introduction: Photodynamic therapy (PDT) with a photosensitizer is available for the treatment of multiple actinic keratoses (AKs) in a restricted skin area or, as it is established, for the field-cancerized skin.Objectives: Our review aims to present the up-to-date literature on skin field cancerization using PDT employing different topical photosensitizers, modified light delivery protocols and combination treatments to obtain excellent efficacy and safety in everyday clinical practice.Methods: We sought PubMed, MEDLINE, Scopus, OVID, Embase, Science Direct, Cochrane Library, Research Gate and Google Scholar for [(aminolevulinic acid OR aminolevulinate) AND photodynamic therapy] with (field-directed OR field cancerization, (actinic keratosis), and (efficacy OR effectiveness OR pain OR tolerability) for studies published until February 2023.Results: Advantages of PDT compared to the other field treatments, including imiquimod, 5-fluorouracil, ingenol mebutate gel and diclofenac, reported better cosmetic outcomes and greater patient satisfaction. On the other hand, some drawbacks of field PDT include pain and treatment duration. Alternate illumination methods have also been investigated, including daylight as a light source. Pretreating the affected area may enhance photosensitizer absorption leading to better therapeutic results, while combinational treatments have also been tested. Patients prefer daylight PDT to traditional light sources since it is more well-tolerated and equally effective. Even as a preventive treatment, field PDT yields promising outcomes, especially for high-risk individuals, including organ transplant recipients.Conclusions: This review provides a thorough display of the field of PDT on cancerized skin, which will facilitate physicians in applying PDT more efficiently and intuitively.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?
    Cazzola, Mario
    Page, Clive P.
    Matera, Maria Gabriella
    Rogliani, Paola
    Hanania, Nicola A.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62 (02)
  • [22] Local immunotherapy: where do we stand
    Passalacqua, G
    Canonica, GW
    REVUE FRANCAISE D ALLERGOLOGIE ET D IMMUNOLOGIE CLINIQUE, 1998, 38 (07): : 657 - 665
  • [23] Depot antipsychotics: Where do we stand?
    Khan, Ahsan Y.
    Salaria, Selman
    Ovais, Muhammad
    Ide, George D.
    ANNALS OF CLINICAL PSYCHIATRY, 2016, 28 (04) : 289 - 298
  • [24] Stem cell therapy in heart failure: Where do we stand today?
    Nair, Nandini
    Gongora, Enrique
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2020, 1866 (04):
  • [25] Daylight photodynamic therapy vs. Conventional photodynamic therapy as skin cancer preventive treatment in patients with face and scalp cancerization: an intra-individual comparison study
    Sotiriou, E.
    Apalla, Z.
    Vrani, F.
    Lazaridou, E.
    Vakirlis, E.
    Lallas, A.
    Ioannides, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (08) : 1303 - 1307
  • [26] Drug Repurposing for the Management of Depression: Where Do We Stand Currently?
    Mohammad Sadeghi, Hosna
    Adeli, Ida
    Mousavi, Taraneh
    Daniali, Marzieh
    Nikfar, Shekoufeh
    Abdollahi, Mohammad
    LIFE-BASEL, 2021, 11 (08):
  • [27] Immunosuppressive treatment for giant cell arteritis: where do we stand?
    Pipitone, N.
    Salvarani, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (02) : S5 - S6
  • [28] Topical photodynamic therapy: the preferred choice for cutaneous field-cancerization?
    Farrar, M. D.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (05) : 1116 - 1117
  • [29] Glycemic effects of simvastatin: Where do we stand?
    Razali, Nor Razida
    Huri, Hasniza Zaman
    Ibrahim, Luqman
    Vethakkan, Shireene Ratna
    Abdullah, Bashar Mudhaffar
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 54 (01)
  • [30] Ebola virus vaccines: Where do we stand?
    Pavot, Vincent
    CLINICAL IMMUNOLOGY, 2016, 173 : 44 - 49